Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in De Novo normal karyotype acute myeloid leukemia (AML)

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 6, 2010, Pages 1811-1816

  Dunna, Nageswara Rao ^a   Rajappa, Senthil ^b   Digumarti, Raghunadharao ^b   Vure, Sugunakar ^a   Kagita, Sailaja ^a   Damineni, Surekha ^a   Rao, V R ^c   Yadav, Satish Kumar ^c   Ravuri, Rajasekhara Reddy ^c   Satti, Vishnupriya ^a  

^a OSMANIA UNIVERSITY   (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^c Anthropological Survey of India   (India)

Author keywords

D 835 mutations; FLT3 ITD; Normal karyotype acute myeloid leukemia; NPM1

Indexed keywords

EID: 79956204667     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bullinger L, Döhner K, Bair E, et al (2004). Use of geneexpression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med, 350, 1605-16.
2. Cheson BD, Bennett JM, Kopecky J, et al (2003). Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol, 21, 4642-9.
3. Döhner K, Schlenk RF, Habdank M, et al (2005). Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics- interaction with other gene mutations. Blood, 106, 3740-6.
4. Dohner H (2008). Implication of the molecular charecterisation of acute myeloid leukemia. Hematology, 412-9.
5. Estey E, Döhner H (2006). Acute myeloid leukaemia. Lancet, 368, 1894-907.
6. Farag SS, Rupert AS, Mrozek K, et al (2005). Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group b study. J Clin Oncol, 23, 482-93.
7. F. Xu T, Thaki Hw yang, Hanada R, et al (1999). Tandem duplication of FLT3 gene is found in acute lymphoblastic leukemia as well as acute myelogenous leukemiabut not in myelodysplastic syndrome or juvenile chronic myelogenous leukemia in children. Br J Haematology, 105, 155-62.
8. Hasan SK, Sazawal S, Dutta P, et al (2007). Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications. Hematology, 12, 99-101.
9. Kottaridis PD, Gale RE, Frew ME, et al (2001). The presence of FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom medical research council AML 10 and 12 trials. Blood, 98, 1752-9.
10. Lee Harris N, Jaffe ES, Diehold J, et al (1999). World health organisation classification of neoplastic diseases of hematopoietic and lymphoid tissues: report of the clinical advisory committee-airlie house, Virginia, November 1997. J Clin Oncol, 17, 3835-49.
11. Mathews V, Thomas M, Srivastava VM, et al (2007). M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica, 92, 994-5.
12. Mead AJ, Linch DC, Hills RK, et al (2007). FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood, 110, 1262-70.
13. Mrózek K, Dohner H, Bloomfield CD (2007). Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol, 14, 106-14.
14. Schlenk RF, Döhner K, Fröhling S, et al (2008). Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Eng J Med, 358, 1909-18.
15. Schnittger S, Schoch C, Kern W, et al (2005). Nucleophosmin gene mutations are predictors of favourable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-9.
16. Suzuki T, Kiyoi H, Ozeki K, et al (2005). Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood, 106, 2854-61.
17. Thiede C, Koch S, Creutzig E, et al (2006). Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107, 4011-20.
18. Verhaak RGW, Goudswaard CS, Van Putten W, et al (2005). Mutations in nucleophosmin NPM1 in acute myeloid leukemia (AML): association with other genetic abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood, 106, 3747-54.
19. Whitman SP, Archer KJ, Feng L, et al (2001). Absence of the wildtype allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res, 61, 7233-9.
20. Yanada M, Matsuo K, Suzuki T, et al (2005). Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia, 19, 1345-9.